- Amir Reichman, BiondVax CEO, represented the company at this year’s BIO CEO & Investor Conference held at the Marriott Marquis, New York, on February 6-8
- His presentation focused on the company’s recent successful pre-clinical in vivo results on its innovative inhaled COVID-19 treatment
- Additional results from the study were release in January 2023, indicating that, compared to the control group, hamsters that received the drug one day after infection had negligible SARS-CoV-2 vital titers in their lungs and experienced a significantly milder and shorter illness
- BiondVax’s management is optimistic that its self-administered inhaled NanoAbs will be highly attractive to at-risk people wishing to proactively, effectively, conveniently, and safely protect themselves
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products mainly for treating infectious and autoimmune diseases, took part in the 2023 BIO CEO & Investor Conference held at the Marriott Marquis, New York. The conference, which took place from February 6-8, offered a platform for stakeholders in the biotech industry, bringing together C-Suite leaders and the investor and banking communities for an opportunity to shape the future investment landscape in the biotechnology sector (https://ibn.fm/zLsni).
Amir Reichman, BiondVax’s CEO, represented the company, focusing his presentation on its recent highly successful pre-clinical in vivo results of its innovative inhaled COVID-19 treatment. He also touched on additional pipeline plans for BiondVax, including, but not limited to, nanosized VHH-antibodies (“NanoAbs”) for the treatment of autoimmune diseases such as psoriasis, asthma, psoriatic arthritis, and macular degeneration (https://ibn.fm/RHS4R).
On January 23, 2023, BiondVax announced additional results from its pre-clinical proof-of-concept study of its innovative NanoAb COVID-19 drug. The study intends to mimic a real-world situation in which, for example, at-risk groups, such as the elderly and people with comorbidities, may proactively protect themselves through the company’s self-administered inhaled NanoAb therapy. The results from this research echoed previously reported data from the same study, which indicated that hamsters that received the drug beginning one day after infection had negligible SARS-CoV-2 vital titers in their lungs and experienced milder and shorter illness compared to the control group (https://ibn.fm/XkVIL).
“We continue to be thrilled with the results of this ongoing trial,” noted Mr. Reichman during the announcement of the study’s results.
“There is strong market demand for COVID prophylactics as evidenced by AstraZeneca’s reported Q1 through Q3 2022 EVUSHELD revenues of $1.5 billion. Data from our trial indicate that our NanoAb may effectively serve as both a therapeutic and protective prophylactic drug, which further enhances its value proposition,” he added.
Evusheld was the only remaining FDA approved drug for protection from COVID illness (as opposed to treatment after infection). On January 26, 2023 the FDA pulled their approval of Evusheld because it is not effective against the new dominant COVID variants (https://ibn.fm/nJ3T4). In the pre-clinical proof-of-concept study, BiondVax’s NanoAbs demonstrated efficacy including against all variants of concern. Evusheld and Paxlovid revenues show there’s still huge and likely growing demand for COVID treatments and BiondVax shows very strong potential to fill these needs with a safe, convenient, and effective inhaled NanoAb treatment.
BiondVax’s management is optimistic that its convenient self-administered inhaled NanoAbs will be highly attractive to at-risk people wishing to proactively, effectively, conveniently, and safely protect themselves. With the COVID treatment market posting $100 billion in revenue in 2022, and the figure expected to increase in the new year, BiondVax is positioning itself to take advantage of this growth (https://ibn.fm/XmWTd). Additionally, with the global biologics market expected to post a CAGR of 7.15% from 2022 to 2030, posting a growth of $366.5 billion in 2021 to $719.94 billion in 2030, BiondVax is confident that its current trajectory will not only contribute to but also benefit from this growth.
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.